Quick Takeaways
- STEMPOINT CAPITAL LP filed SCHEDULE 13G for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO).
- Disclosed ownership: 7.2%.
- Date of event: 30 Sep 2025.
STEMPOINT CAPITAL LP - 30 Sep 2025 SCHEDULE 13G Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)
- Filing Manager
- STEMPOINT CAPITAL LP
- Reporting Manager
- StemPoint Capital LP
- Symbol
- XLO
- Shares outstanding
- 55,555,556 shares
- Disclosed Ownership
- 4,000,000 shares
- Ownership
- 7.2%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 10:00:24 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"STEMPOINT CAPITAL LP disclosed 7.2% ownership in Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 10:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| StemPoint Capital LP | 7.2% | 4,000,000 | 0 | 4,000,000 | /s/ Sean C. Tan | Sean C. Tan, Authorized Signatory | |
| StemPoint Capital Management GP LLC | 7.2% | 4,000,000 | 0 | 4,000,000 | /s/ Sean C. Tan | Sean C. Tan, Authorized Signatory | |
| Michelle Ross | 7.2% | 4,000,000 | 0 | 4,000,000 | /s/ Michelle Ross | Michelle Ross |